Compare GASS & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GASS | CRBU |
|---|---|---|
| Founded | 2004 | 2011 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 253.4M | 203.9M |
| IPO Year | 2005 | 2021 |
| Metric | GASS | CRBU |
|---|---|---|
| Price | $6.96 | $1.71 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $9.33 |
| AVG Volume (30 Days) | 129.4K | ★ 1.0M |
| Earning Date | 11-25-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.66 | N/A |
| Revenue | ★ $177,257,115.00 | $9,295,000.00 |
| Revenue This Year | $5.86 | N/A |
| Revenue Next Year | N/A | $4.96 |
| P/E Ratio | $4.32 | ★ N/A |
| Revenue Growth | ★ 12.23 | N/A |
| 52 Week Low | $4.82 | $0.66 |
| 52 Week High | $8.18 | $3.54 |
| Indicator | GASS | CRBU |
|---|---|---|
| Relative Strength Index (RSI) | 54.62 | 36.21 |
| Support Level | $6.69 | $1.82 |
| Resistance Level | $7.25 | $1.91 |
| Average True Range (ATR) | 0.20 | 0.10 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 51.28 | 1.92 |
StealthGas Inc is an international shipping transportation company. It owns liquefied petroleum gas (LPG) pressurized carriers and provides international seaborne transportation services to LPG producers and users, as well as crude oil and product carriers to oil producers, refineries, and commodities traders. The company carriers carry various petroleum gas products in liquefied forms, such as propane, butane, butadiene, isopropane, propylene, and vinyl chloride monomer, which are all byproducts of the production of crude oil and natural gas.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.